Shilpa Medicare and Gilead Sciences have inked pact with United Nations-backed Medicines Patent Pool by entering into agreement to increase the access to medicines for HIV/AIDS treatment. With this initiative, the company will be able to produce five key HIV medicines for sale in over 100 countries depending on the medicine.
As per the agreement, the Karnataka-based firm can produce tenofovir, emtricitabine, cobicistat, elvitegravir and a combination of the four known as -the Quad. For this it will pay 3-5% royalty to the patent-holder Gilead, depending on the medicine.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: